Literature DB >> 25318555

Aquaporin-2-guided tolvaptan therapy in patients with congestive heart failure accompanied by chronic kidney disease.

Teruhiko Imamura1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25318555     DOI： 10.1536/ihj.14-217

Source DB:  PubMed          Journal:  Int Heart J        ISSN： 1349-2365            Impact factor:   1.862


× No keyword cloud information.
  2 in total

Review 1.  Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure.

Authors:  Teruhiko Imamura; Koichiro Kinugawa
Journal:  Int J Mol Sci       Date:  2016-01-14       Impact factor: 5.923

2.  Different Effects of Tolvaptan in Patients with Idiopathic Membranous Nephropathy with Nephrotic Syndrome.

Authors:  Atsushi Tanaka; Tsukasa Nakamura; Eiichi Sato; Yoshihiko Ueda; Koichi Node
Journal:  Intern Med       Date:  2017-01-15       Impact factor: 1.271
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.